CN116507353A - 治疗黑皮质素-4受体通路相关病症的方法 - Google Patents
治疗黑皮质素-4受体通路相关病症的方法 Download PDFInfo
- Publication number
- CN116507353A CN116507353A CN202180071771.8A CN202180071771A CN116507353A CN 116507353 A CN116507353 A CN 116507353A CN 202180071771 A CN202180071771 A CN 202180071771A CN 116507353 A CN116507353 A CN 116507353A
- Authority
- CN
- China
- Prior art keywords
- arg
- cys
- ala
- seq
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 138
- 230000037361 pathway Effects 0.000 title claims abstract description 100
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title claims abstract description 12
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title claims abstract description 10
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims abstract description 288
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims abstract description 288
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 208
- 239000000556 agonist Substances 0.000 claims abstract description 201
- 208000008589 Obesity Diseases 0.000 claims abstract description 86
- 235000020824 obesity Nutrition 0.000 claims abstract description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- 208000032841 Bulimia Diseases 0.000 claims abstract description 19
- 206010004716 Binge eating Diseases 0.000 claims abstract description 18
- 208000014679 binge eating disease Diseases 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 122
- 230000035772 mutation Effects 0.000 claims description 103
- -1 CCK Proteins 0.000 claims description 75
- 108700028369 Alleles Proteins 0.000 claims description 73
- 208000011580 syndromic disease Diseases 0.000 claims description 73
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 62
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 60
- 125000002252 acyl group Chemical group 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 45
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 230000037430 deletion Effects 0.000 claims description 39
- 238000012217 deletion Methods 0.000 claims description 39
- 125000000304 alkynyl group Chemical group 0.000 claims description 38
- 208000035475 disorder Diseases 0.000 claims description 38
- 125000003107 substituted aryl group Chemical group 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 28
- 230000037396 body weight Effects 0.000 claims description 25
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 claims description 22
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 claims description 22
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims description 21
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 claims description 21
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 20
- 101000633968 Homo sapiens Tubby protein homolog Proteins 0.000 claims description 20
- 230000001270 agonistic effect Effects 0.000 claims description 20
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 19
- 101001137640 Homo sapiens Kinase suppressor of Ras 2 Proteins 0.000 claims description 19
- 101001099922 Homo sapiens Retinoic acid-induced protein 1 Proteins 0.000 claims description 19
- 101001120868 Homo sapiens Meckel syndrome type 1 protein Proteins 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 18
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 17
- 101000602926 Homo sapiens Nuclear receptor coactivator 1 Proteins 0.000 claims description 17
- 101001088739 Homo sapiens Probable inactive ribonuclease-like protein 12 Proteins 0.000 claims description 17
- 101000651467 Homo sapiens Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 claims description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 17
- 102100038470 Retinoic acid-induced protein 1 Human genes 0.000 claims description 17
- 102100029249 Tubby protein homolog Human genes 0.000 claims description 17
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 16
- 101000769028 Homo sapiens ADP-ribosylation factor-like protein 6 Proteins 0.000 claims description 16
- 101000749824 Homo sapiens Connector enhancer of kinase suppressor of ras 2 Proteins 0.000 claims description 16
- 101000584427 Homo sapiens Homeobox protein orthopedia Proteins 0.000 claims description 16
- 101000961172 Homo sapiens Intraflagellar transport protein 27 homolog Proteins 0.000 claims description 16
- 101000963761 Homo sapiens Melanocortin-2 receptor accessory protein 2 Proteins 0.000 claims description 16
- 101001130305 Homo sapiens Ras-related protein Rab-23 Proteins 0.000 claims description 16
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 claims description 16
- 102100021000 Kinase suppressor of Ras 2 Human genes 0.000 claims description 16
- 102100026048 Meckel syndrome type 1 protein Human genes 0.000 claims description 16
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 16
- 238000001802 infusion Methods 0.000 claims description 16
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 claims description 15
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 15
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 claims description 15
- 102100040148 Melanocortin-2 receptor accessory protein 2 Human genes 0.000 claims description 15
- 102100031522 Ras-related protein Rab-23 Human genes 0.000 claims description 15
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 claims description 15
- 238000010254 subcutaneous injection Methods 0.000 claims description 15
- 239000007929 subcutaneous injection Substances 0.000 claims description 15
- 102100028359 ADP-ribosylation factor-like protein 6 Human genes 0.000 claims description 14
- 201000009150 Bardet-Biedl syndrome 19 Diseases 0.000 claims description 14
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 claims description 14
- 150000008574 D-amino acids Chemical class 0.000 claims description 14
- 102100030641 Homeobox protein orthopedia Human genes 0.000 claims description 14
- 101000945747 Homo sapiens Cilia- and flagella-associated protein 418 Proteins 0.000 claims description 14
- 101000616300 Homo sapiens Leucine zipper transcription factor-like protein 1 Proteins 0.000 claims description 14
- 101001070479 Homo sapiens Probable G-protein coupled receptor 101 Proteins 0.000 claims description 14
- 102100039343 Intraflagellar transport protein 27 homolog Human genes 0.000 claims description 14
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 claims description 14
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 13
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 13
- 101000833170 Homo sapiens AF4/FMR2 family member 4 Proteins 0.000 claims description 13
- 101000959328 Homo sapiens Adenylate cyclase type 3 Proteins 0.000 claims description 13
- 101000775481 Homo sapiens Adenylate cyclase type 8 Proteins 0.000 claims description 13
- 102100024381 AF4/FMR2 family member 4 Human genes 0.000 claims description 12
- 102100021975 CREB-binding protein Human genes 0.000 claims description 12
- 102100034761 Cilia- and flagella-associated protein 418 Human genes 0.000 claims description 12
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 claims description 12
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims description 12
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 12
- 101001010835 Homo sapiens Intraflagellar transport protein 74 homolog Proteins 0.000 claims description 12
- 102100021803 Leucine zipper transcription factor-like protein 1 Human genes 0.000 claims description 12
- 108010088847 Peptide YY Proteins 0.000 claims description 12
- 102100029909 Peptide YY Human genes 0.000 claims description 12
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 claims description 12
- 102100020877 WD repeat-containing and planar cell polarity effector protein fritz homolog Human genes 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 230000002267 hypothalamic effect Effects 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 claims description 11
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims description 11
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 11
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 claims description 11
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 claims description 11
- 101000979216 Homo sapiens Necdin Proteins 0.000 claims description 11
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 claims description 11
- 101001067178 Homo sapiens Plexin-A4 Proteins 0.000 claims description 11
- 101000610543 Homo sapiens Prokineticin-2 Proteins 0.000 claims description 11
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims description 11
- 102100023210 Necdin Human genes 0.000 claims description 11
- 102100024315 Pericentrin Human genes 0.000 claims description 11
- 102100034382 Plexin-A1 Human genes 0.000 claims description 11
- 102100034385 Plexin-A4 Human genes 0.000 claims description 11
- 102100034137 Probable G-protein coupled receptor 101 Human genes 0.000 claims description 11
- 102100040125 Prokineticin-2 Human genes 0.000 claims description 11
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 102000054930 Agouti-Related Human genes 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 102100038733 CREB3 regulatory factor Human genes 0.000 claims description 10
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims description 10
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims description 10
- 102100024646 Cell adhesion molecule 2 Human genes 0.000 claims description 10
- 102100028901 Cullin-4B Human genes 0.000 claims description 10
- 101800001586 Ghrelin Proteins 0.000 claims description 10
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims description 10
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims description 10
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 claims description 10
- 101000692980 Homo sapiens PHD finger protein 6 Proteins 0.000 claims description 10
- 101001117010 Homo sapiens Pericentrin Proteins 0.000 claims description 10
- 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 claims description 10
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 10
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 10
- 102100031419 Insulin receptor substrate 4 Human genes 0.000 claims description 10
- 102100029997 Intraflagellar transport protein 74 homolog Human genes 0.000 claims description 10
- 150000008575 L-amino acids Chemical class 0.000 claims description 10
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 claims description 10
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 10
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 10
- 108090000770 Neuropilin-2 Proteins 0.000 claims description 10
- 102000004213 Neuropilin-2 Human genes 0.000 claims description 10
- 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 claims description 10
- 102100030275 PH-interacting protein Human genes 0.000 claims description 10
- 102100026365 PHD finger protein 6 Human genes 0.000 claims description 10
- 102100034381 Plexin-A2 Human genes 0.000 claims description 10
- 102100034386 Plexin-A3 Human genes 0.000 claims description 10
- 102100027974 Semaphorin-3A Human genes 0.000 claims description 10
- 108010090319 Semaphorin-3A Proteins 0.000 claims description 10
- 102100027979 Semaphorin-3B Human genes 0.000 claims description 10
- 108010021098 Uncoupling Protein 3 Proteins 0.000 claims description 10
- 102000008200 Uncoupling Protein 3 Human genes 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- KUBWJGWIWGGEPZ-UHFFFAOYSA-N 1-[amino(ethoxy)phosphoryl]oxy-4-nitrobenzene Chemical compound CCOP(N)(=O)OC1=CC=C([N+]([O-])=O)C=C1 KUBWJGWIWGGEPZ-UHFFFAOYSA-N 0.000 claims description 9
- 101100225890 Aplysia californica ENPP gene Proteins 0.000 claims description 9
- 102100022802 BTB/POZ domain-containing protein KCTD15 Human genes 0.000 claims description 9
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 9
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 9
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 9
- 101000916231 Homo sapiens Cullin-4B Proteins 0.000 claims description 9
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims description 9
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 claims description 9
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 claims description 9
- 101000994101 Homo sapiens Insulin receptor substrate 4 Proteins 0.000 claims description 9
- 101000599629 Homo sapiens Insulin-induced gene 2 protein Proteins 0.000 claims description 9
- 101000603173 Homo sapiens Neuroligin-2 Proteins 0.000 claims description 9
- 101000978937 Homo sapiens Nuclear receptor subfamily 0 group B member 2 Proteins 0.000 claims description 9
- 101001067184 Homo sapiens Plexin-A3 Proteins 0.000 claims description 9
- 101000667110 Homo sapiens Vacuolar protein sorting-associated protein 13B Proteins 0.000 claims description 9
- 102100037970 Insulin-induced gene 2 protein Human genes 0.000 claims description 9
- 102100023924 Kinase D-interacting substrate of 220 kDa Human genes 0.000 claims description 9
- 102100026047 Meckelin Human genes 0.000 claims description 9
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 9
- 102100037732 Neuroendocrine convertase 2 Human genes 0.000 claims description 9
- 102100038939 Neuroligin-2 Human genes 0.000 claims description 9
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 9
- 102100024369 Phosphatidylinositol polyphosphate 5-phosphatase type IV Human genes 0.000 claims description 9
- 102100031481 Protein transport protein Sec16B Human genes 0.000 claims description 9
- 108010085603 SFLLRNPND Proteins 0.000 claims description 9
- 102100034803 Small nuclear ribonucleoprotein-associated protein N Human genes 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 108010039827 snRNP Core Proteins Proteins 0.000 claims description 9
- 102100033567 Acyl-CoA-binding domain-containing protein 7 Human genes 0.000 claims description 8
- 102100021982 Coiled-coil domain-containing protein 28B Human genes 0.000 claims description 8
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 8
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims description 8
- 101000801606 Homo sapiens Acyl-CoA-binding domain-containing protein 7 Proteins 0.000 claims description 8
- 101000974798 Homo sapiens BTB/POZ domain-containing protein KCTD15 Proteins 0.000 claims description 8
- 101000760622 Homo sapiens Cell adhesion molecule 2 Proteins 0.000 claims description 8
- 101000896972 Homo sapiens Coiled-coil domain-containing protein 28B Proteins 0.000 claims description 8
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims description 8
- 101000975939 Homo sapiens Kinase D-interacting substrate of 220 kDa Proteins 0.000 claims description 8
- 101001120864 Homo sapiens Meckelin Proteins 0.000 claims description 8
- 101000577080 Homo sapiens Mitochondrial-processing peptidase subunit alpha Proteins 0.000 claims description 8
- 101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 claims description 8
- 101001053329 Homo sapiens Phosphatidylinositol polyphosphate 5-phosphatase type IV Proteins 0.000 claims description 8
- 101000654452 Homo sapiens Protein transport protein Sec16B Proteins 0.000 claims description 8
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 claims description 8
- 101000632270 Homo sapiens Semaphorin-3B Proteins 0.000 claims description 8
- 101000650811 Homo sapiens Semaphorin-3D Proteins 0.000 claims description 8
- 101000650804 Homo sapiens Semaphorin-3E Proteins 0.000 claims description 8
- 101000650806 Homo sapiens Semaphorin-3F Proteins 0.000 claims description 8
- 101000650808 Homo sapiens Semaphorin-3G Proteins 0.000 claims description 8
- 101000692107 Homo sapiens Syndecan-3 Proteins 0.000 claims description 8
- 101001104110 Homo sapiens X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Proteins 0.000 claims description 8
- 101710151321 Melanostatin Proteins 0.000 claims description 8
- 102100027746 Semaphorin-3D Human genes 0.000 claims description 8
- 102100027752 Semaphorin-3E Human genes 0.000 claims description 8
- 102100027751 Semaphorin-3F Human genes 0.000 claims description 8
- 102100027750 Semaphorin-3G Human genes 0.000 claims description 8
- 102100026084 Syndecan-3 Human genes 0.000 claims description 8
- 102100039113 Vacuolar protein sorting-associated protein 13B Human genes 0.000 claims description 8
- 102100040089 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 Human genes 0.000 claims description 8
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 102100034120 Golgin subfamily A member 6A Human genes 0.000 claims description 5
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 5
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 claims description 5
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 claims description 5
- 101710119304 PH-interacting protein Proteins 0.000 claims description 5
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 claims description 5
- 102100035318 Transmembrane protein 18 Human genes 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229940071643 prefilled syringe Drugs 0.000 claims description 5
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims description 4
- 101000597758 Homo sapiens Transmembrane protein 18 Proteins 0.000 claims description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 4
- 108060006706 SRC Proteins 0.000 claims description 4
- 102000001332 SRC Human genes 0.000 claims description 4
- 102000003621 TRPC5 Human genes 0.000 claims description 4
- 101150042815 TRPC5 gene Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 claims description 3
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 claims description 2
- 238000013542 behavioral therapy Methods 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 102100032153 Adenylate cyclase type 8 Human genes 0.000 claims 1
- 101100095739 Arabidopsis thaliana SHH2 gene Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 102000012004 Ghrelin Human genes 0.000 claims 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 claims 1
- 101000957828 Homo sapiens CREB3 regulatory factor Proteins 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 claims 1
- 101001018494 Homo sapiens Pro-MCH Proteins 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- 101000680845 Luffa aegyptiaca Ribosome-inactivating protein luffin P1 Proteins 0.000 claims 1
- 102100033721 Pro-MCH Human genes 0.000 claims 1
- 102100028427 Pro-neuropeptide Y Human genes 0.000 claims 1
- 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 101
- 238000011282 treatment Methods 0.000 description 88
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 86
- 229940091173 hydantoin Drugs 0.000 description 86
- 150000003839 salts Chemical class 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 58
- 239000000203 mixture Substances 0.000 description 56
- 235000003642 hunger Nutrition 0.000 description 50
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 210000004081 cilia Anatomy 0.000 description 36
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 230000036772 blood pressure Effects 0.000 description 30
- 230000037406 food intake Effects 0.000 description 30
- 235000012631 food intake Nutrition 0.000 description 30
- 230000007423 decrease Effects 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 239000000523 sample Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 239000002865 melanocortin Substances 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 25
- 108010008364 Melanocortins Proteins 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 24
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 22
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 21
- 230000004044 response Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 17
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 17
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 230000011664 signaling Effects 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 102100039659 Adenylate cyclase type 3 Human genes 0.000 description 14
- 230000009395 genetic defect Effects 0.000 description 14
- 230000000977 initiatory effect Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 13
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 13
- 230000032258 transport Effects 0.000 description 13
- 102000016267 Leptin Human genes 0.000 description 12
- 108010092277 Leptin Proteins 0.000 description 12
- 230000007547 defect Effects 0.000 description 12
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 12
- 229940039781 leptin Drugs 0.000 description 12
- 230000002103 transcriptional effect Effects 0.000 description 12
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 11
- 208000026350 Inborn Genetic disease Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000016361 genetic disease Diseases 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000003068 static effect Effects 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 10
- 102100032378 Carboxypeptidase E Human genes 0.000 description 10
- 108010058255 Carboxypeptidase H Proteins 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 208000001022 morbid obesity Diseases 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 101710183427 CREB3 regulatory factor Proteins 0.000 description 9
- 101800001982 Cholecystokinin Proteins 0.000 description 9
- 102100025841 Cholecystokinin Human genes 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- 102100031775 Leptin receptor Human genes 0.000 description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 description 9
- 108010041559 Methionine Sulfoxide Reductases Proteins 0.000 description 9
- 102000000532 Methionine Sulfoxide Reductases Human genes 0.000 description 9
- 101150023417 PPARG gene Proteins 0.000 description 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 229940107137 cholecystokinin Drugs 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 108010019813 leptin receptors Proteins 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 9
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 8
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 101150110867 MC4R gene Proteins 0.000 description 8
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 8
- 102000006437 Proprotein Convertases Human genes 0.000 description 8
- 108010044159 Proprotein Convertases Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 8
- 230000036528 appetite Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 8
- 102400000739 Corticotropin Human genes 0.000 description 7
- 101800000414 Corticotropin Proteins 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 101000893100 Homo sapiens Protein fantom Proteins 0.000 description 7
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 7
- 102400000064 Neuropeptide Y Human genes 0.000 description 7
- 102100040970 Protein fantom Human genes 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 7
- 229960000258 corticotropin Drugs 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 6
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 6
- 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 description 6
- 206010058359 Hypogonadism Diseases 0.000 description 6
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 6
- 102100028333 MAGE-like protein 2 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000004777 loss-of-function mutation Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000037351 starvation Effects 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 102100027883 Bardet-Biedl syndrome 2 protein Human genes 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 102000003693 Hedgehog Proteins Human genes 0.000 description 5
- 108090000031 Hedgehog Proteins Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 5
- 101001126819 Homo sapiens PH-interacting protein Proteins 0.000 description 5
- 101000845196 Homo sapiens Tetratricopeptide repeat protein 8 Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 108090000787 Subtilisin Proteins 0.000 description 5
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
- 102100031271 Tetratricopeptide repeat protein 8 Human genes 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 108010023456 adenylate cyclase 3 Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000006583 body weight regulation Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000008632 circadian clock Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004049 epigenetic modification Effects 0.000 description 5
- 229960002870 gabapentin Drugs 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000000865 phosphorylative effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 description 4
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 4
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 4
- 101000697666 Homo sapiens Bardet-Biedl syndrome 5 protein Proteins 0.000 description 4
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 description 4
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 4
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
- 208000036626 Mental retardation Diseases 0.000 description 4
- 102100028762 Neuropilin-1 Human genes 0.000 description 4
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 4
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 4
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000003793 centrosome Anatomy 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000008358 core component Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000019439 energy homeostasis Effects 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 4
- 201000008980 hyperinsulinism Diseases 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 3
- 108010088547 ARNTL Transcription Factors Proteins 0.000 description 3
- 102100032360 Alstrom syndrome protein 1 Human genes 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 102100027882 Bardet-Biedl syndrome 7 protein Human genes 0.000 description 3
- 101100454129 Caenorhabditis elegans ksr-2 gene Proteins 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 3
- 102100039563 ETS translocation variant 1 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100029602 Eukaryotic translation initiation factor 4B Human genes 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 102100021889 Helix-loop-helix protein 2 Human genes 0.000 description 3
- 101000797795 Homo sapiens Alstrom syndrome protein 1 Proteins 0.000 description 3
- 101000697669 Homo sapiens Bardet-Biedl syndrome 7 protein Proteins 0.000 description 3
- 101000715664 Homo sapiens Centrosomal protein of 290 kDa Proteins 0.000 description 3
- 101000840282 Homo sapiens Eukaryotic translation initiation factor 4B Proteins 0.000 description 3
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 3
- 101000963759 Homo sapiens Melanocortin-2 receptor accessory protein Proteins 0.000 description 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 3
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 3
- 101100516055 Homo sapiens NCOA1 gene Proteins 0.000 description 3
- 101000738546 Homo sapiens Protein PTHB1 Proteins 0.000 description 3
- 201000006347 Intellectual Disability Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102100030874 Leptin Human genes 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 3
- 229940124647 MEK inhibitor Drugs 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000004378 Melanocortin Receptors Human genes 0.000 description 3
- 108090000950 Melanocortin Receptors Proteins 0.000 description 3
- 102100040147 Melanocortin-2 receptor accessory protein Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 3
- 102100028647 Mu-type opioid receptor Human genes 0.000 description 3
- 102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 3
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102100037873 Protein PTHB1 Human genes 0.000 description 3
- 238000010357 RNA editing Methods 0.000 description 3
- 230000026279 RNA modification Effects 0.000 description 3
- 102100031772 Short transient receptor potential channel 5 Human genes 0.000 description 3
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 3
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 description 3
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 3
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000037041 intracellular level Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229950002454 lysergide Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000037323 metabolic rate Effects 0.000 description 3
- LBCGUKCXRVUULK-QGZVFWFLSA-N n-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1h-imidazol-1-yl)-6-methylpyrimidin-4-yl]-d-prolinamide Chemical compound N=1C(C)=CC(N2[C@H](CCC2)C(=O)NCCC=2C=C3OCOC3=CC=2)=NC=1N1C=CN=C1 LBCGUKCXRVUULK-QGZVFWFLSA-N 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108010036962 polypeptide 3 90kDa ribosomal protein S6 kinase Proteins 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000007781 signaling event Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 description 2
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 2
- 102100033714 40S ribosomal protein S6 Human genes 0.000 description 2
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 101710184656 AF4/FMR2 family member 4 Proteins 0.000 description 2
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 2
- 102100021661 Aryl hydrocarbon receptor nuclear translocator-like protein 2 Human genes 0.000 description 2
- HSPSXROIMXIJQW-BQBZGAKWSA-N Asp-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 HSPSXROIMXIJQW-BQBZGAKWSA-N 0.000 description 2
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 2
- 102100035777 BBSome-interacting protein 1 Human genes 0.000 description 2
- 102100021296 Bardet-Biedl syndrome 10 protein Human genes 0.000 description 2
- 102100021297 Bardet-Biedl syndrome 12 protein Human genes 0.000 description 2
- 201000009152 Bardet-Biedl syndrome 18 Diseases 0.000 description 2
- 208000021351 Bardet-Biedl syndrome 20 Diseases 0.000 description 2
- 102100027884 Bardet-Biedl syndrome 4 protein Human genes 0.000 description 2
- 102100027878 Bardet-Biedl syndrome 5 protein Human genes 0.000 description 2
- 208000006146 Borjeson-Forssman-Lehmann syndrome Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 208000032081 Cabezas type X-linked intellectual disability Diseases 0.000 description 2
- 101100276977 Caenorhabditis elegans dapk-1 gene Proteins 0.000 description 2
- 101100534223 Caenorhabditis elegans src-1 gene Proteins 0.000 description 2
- 201000002926 Carpenter syndrome Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102100027426 Centriolar coiled-coil protein of 110 kDa Human genes 0.000 description 2
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 2
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 2
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 102100022263 Disks large homolog 3 Human genes 0.000 description 2
- 108010045061 Dysbindin Proteins 0.000 description 2
- 102000005611 Dysbindin Human genes 0.000 description 2
- 208000004929 Facial Paralysis Diseases 0.000 description 2
- 206010051267 Facial paresis Diseases 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- HKTRDWYCAUTRRL-YUMQZZPRSA-N Glu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-YUMQZZPRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 101000656896 Homo sapiens 40S ribosomal protein S6 Proteins 0.000 description 2
- 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 2
- 101000997570 Homo sapiens Appetite-regulating hormone Proteins 0.000 description 2
- 101000874276 Homo sapiens BBSome-interacting protein 1 Proteins 0.000 description 2
- 101000894732 Homo sapiens Bardet-Biedl syndrome 10 protein Proteins 0.000 description 2
- 101000894739 Homo sapiens Bardet-Biedl syndrome 12 protein Proteins 0.000 description 2
- 101000697700 Homo sapiens Bardet-Biedl syndrome 2 protein Proteins 0.000 description 2
- 101000697660 Homo sapiens Bardet-Biedl syndrome 4 protein Proteins 0.000 description 2
- 101000725200 Homo sapiens Centriolar coiled-coil protein of 110 kDa Proteins 0.000 description 2
- 101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 2
- 101000902100 Homo sapiens Disks large homolog 3 Proteins 0.000 description 2
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 2
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 2
- 101000897700 Homo sapiens Helix-loop-helix protein 2 Proteins 0.000 description 2
- 101000960114 Homo sapiens Intraflagellar transport protein 172 homolog Proteins 0.000 description 2
- 101000573510 Homo sapiens McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin Proteins 0.000 description 2
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 2
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 2
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 2
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 2
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 2
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 2
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 2
- 101001048695 Homo sapiens RNA polymerase II elongation factor ELL Proteins 0.000 description 2
- 101000707152 Homo sapiens SH2B adapter protein 1 Proteins 0.000 description 2
- 101000846117 Homo sapiens Short transient receptor potential channel 5 Proteins 0.000 description 2
- 101000703681 Homo sapiens Single-minded homolog 1 Proteins 0.000 description 2
- 101000657580 Homo sapiens Small nuclear ribonucleoprotein-associated protein N Proteins 0.000 description 2
- 101001074042 Homo sapiens Transcriptional activator GLI3 Proteins 0.000 description 2
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 206010021034 Hypometabolism Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000032578 Inherited retinal disease Diseases 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 102100039929 Intraflagellar transport protein 172 homolog Human genes 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 102100026300 McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin Human genes 0.000 description 2
- 201000008643 Meckel syndrome Diseases 0.000 description 2
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 2
- 101710148380 Melanocortin-2 receptor accessory protein 2 Proteins 0.000 description 2
- 102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 2
- 101710129905 Melanotropin beta Proteins 0.000 description 2
- 102400000744 Melanotropin gamma Human genes 0.000 description 2
- 101800000520 Melanotropin gamma Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 2
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 2
- 208000007379 Muscle Hypotonia Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 101710187339 Neuronal growth regulator 1 Proteins 0.000 description 2
- 101100247323 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-2 gene Proteins 0.000 description 2
- 101710092553 Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 2
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 101150093308 POMC gene Proteins 0.000 description 2
- 101100298837 Parengyodontium album PROK gene Proteins 0.000 description 2
- 241000238661 Periplaneta Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101710103829 Prokineticin-2 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102100023449 RNA polymerase II elongation factor ELL Human genes 0.000 description 2
- 108050002327 Ras-related protein Rab-23 Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 208000032430 Retinal dystrophy Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102100031770 SH2B adapter protein 1 Human genes 0.000 description 2
- 108700022176 SOS1 Proteins 0.000 description 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 2
- 101710199438 Semaphorin-3B Proteins 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 102100031980 Single-minded homolog 1 Human genes 0.000 description 2
- 206010072610 Skeletal dysplasia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 2
- 101150100839 Sos1 gene Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000010632 Transcription Factor Activity Effects 0.000 description 2
- 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 2
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000006690 co-activation Effects 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 229940052810 complex b Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000021316 daily nutritional intake Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 201000006321 fundus dystrophy Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000009459 hedgehog signaling Effects 0.000 description 2
- 102000045353 human AFF4 Human genes 0.000 description 2
- 102000047980 human ARL6 Human genes 0.000 description 2
- 102000050618 human GPR101 Human genes 0.000 description 2
- 102000045993 human HTR2C Human genes 0.000 description 2
- 102000050439 human IFT74 Human genes 0.000 description 2
- 102000047208 human KSR2 Human genes 0.000 description 2
- 102000052493 human LZTFL1 Human genes 0.000 description 2
- 102000046545 human MKS1 Human genes 0.000 description 2
- 102000047165 human MRAP2 Human genes 0.000 description 2
- 102000053617 human OTP Human genes 0.000 description 2
- 102000057222 human PROK2 Human genes 0.000 description 2
- 102000056678 human RAB23 Human genes 0.000 description 2
- 102000057736 human TBX3 Human genes 0.000 description 2
- 102000055818 human TRIM32 Human genes 0.000 description 2
- 102000055029 human TUB Human genes 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- MSVZUEGLXXVUJS-UHFFFAOYSA-N hydron;n-(2-piperidin-1-ylethyl)-n-(pyridin-2-ylmethyl)aniline;chloride Chemical compound Cl.C=1C=CC=NC=1CN(C=1C=CC=CC=1)CCN1CCCCC1 MSVZUEGLXXVUJS-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000018770 reduced food intake Nutrition 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 201000001872 syndromic X-linked intellectual disability Cabezas type Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000000476 thermogenic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 2
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- ZCVBHUKHCDVNRY-ZLELNMGESA-N (2s)-2-aminohexanoic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound CCCC[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O ZCVBHUKHCDVNRY-ZLELNMGESA-N 0.000 description 1
- RPFGGVOFYMYSEB-MGEKJXBCSA-N (2s,4s,5r,6r)-6-[(1r,2r)-1-[(2s,4s,5r,6r)-5-acetamido-6-[(1r,2r)-3-acetyloxy-1,2-dihydroxypropyl]-2-carboxy-4-hydroxyoxan-2-yl]oxy-2,3-dihydroxypropyl]-2-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)\C=C\CCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(O)=O)[C@@H](O)C2)[C@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)COC(C)=O)C(O)=O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 RPFGGVOFYMYSEB-MGEKJXBCSA-N 0.000 description 1
- 125000006823 (C1-C6) acyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- 101710112812 14-3-3 protein Proteins 0.000 description 1
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 1
- 102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- GDGFTEGUDDPSIT-UHFFFAOYSA-N 4-pyrimidin-4-ylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=NC=N1 GDGFTEGUDDPSIT-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- 102000041188 ARF family Human genes 0.000 description 1
- 108091061173 ARF family Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100039660 Adenylate cyclase type 4 Human genes 0.000 description 1
- 229930183007 Adipostatin Natural products 0.000 description 1
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 1
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- JQDFGZKKXBEANU-IMJSIDKUSA-N Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(O)=O JQDFGZKKXBEANU-IMJSIDKUSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 101710101214 BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101710185536 BTB/POZ domain-containing protein KCTD15 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000409333 Cabeza Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101150040124 Cadm2 gene Proteins 0.000 description 1
- 101100165205 Caenorhabditis elegans bbs-2 gene Proteins 0.000 description 1
- 101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 description 1
- 101100256309 Caenorhabditis elegans sdc-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710197434 Cell adhesion molecule 2 Proteins 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000009343 Cornelia de Lange syndrome Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 102100029376 Cryptochrome-1 Human genes 0.000 description 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 1
- 102100026359 Cyclic AMP-responsive element-binding protein 1 Human genes 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- CXISPYVYMQWFLE-GSVOUGTGSA-N D-Ala-Gly Chemical compound C[C@@H](N)C(=O)NCC(O)=O CXISPYVYMQWFLE-GSVOUGTGSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000003471 De Lange Syndrome Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 102100034295 Eukaryotic translation initiation factor 3 subunit A Human genes 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- 208000002111 Eye Abnormalities Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101100180045 Gallus gallus ISL1 gene Proteins 0.000 description 1
- 108010008945 General Transcription Factors Proteins 0.000 description 1
- 102000006580 General Transcription Factors Human genes 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010061199 Head deformity Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101710149236 Helix-loop-helix protein 2 Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 101710155878 Histone acetyltransferase p300 Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 description 1
- 101100056305 Homo sapiens ARL6 gene Proteins 0.000 description 1
- 101000580577 Homo sapiens ATP-dependent DNA helicase Q4 Proteins 0.000 description 1
- 101000959333 Homo sapiens Adenylate cyclase type 4 Proteins 0.000 description 1
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101000777555 Homo sapiens CCN family member 3 Proteins 0.000 description 1
- 101100005863 Homo sapiens CEP290 gene Proteins 0.000 description 1
- 101100168909 Homo sapiens CUL4B gene Proteins 0.000 description 1
- 101000919351 Homo sapiens Cryptochrome-1 Proteins 0.000 description 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101100054166 Homo sapiens HTR2C gene Proteins 0.000 description 1
- 101100072309 Homo sapiens IFT74 gene Proteins 0.000 description 1
- 101000961120 Homo sapiens Intraflagellar transport protein 25 homolog Proteins 0.000 description 1
- 101001010731 Homo sapiens Intraflagellar transport protein 81 homolog Proteins 0.000 description 1
- 101100127009 Homo sapiens KIDINS220 gene Proteins 0.000 description 1
- 101100455822 Homo sapiens LZTFL1 gene Proteins 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 101100077193 Homo sapiens MKS1 gene Proteins 0.000 description 1
- 101000720986 Homo sapiens Melanopsin Proteins 0.000 description 1
- 101000581507 Homo sapiens Methyl-CpG-binding domain protein 1 Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 101000996111 Homo sapiens Neuroligin-4, X-linked Proteins 0.000 description 1
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 101000978926 Homo sapiens Nuclear receptor subfamily 1 group D member 1 Proteins 0.000 description 1
- 101100350558 Homo sapiens OTP gene Proteins 0.000 description 1
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 1
- 101100353424 Homo sapiens PROK2 gene Proteins 0.000 description 1
- 101001134861 Homo sapiens Pericentriolar material 1 protein Proteins 0.000 description 1
- 101000579484 Homo sapiens Period circadian protein homolog 1 Proteins 0.000 description 1
- 101001126582 Homo sapiens Post-GPI attachment to proteins factor 3 Proteins 0.000 description 1
- 101001123801 Homo sapiens Protein POF1B Proteins 0.000 description 1
- 101000928408 Homo sapiens Protein diaphanous homolog 2 Proteins 0.000 description 1
- 101100300841 Homo sapiens RAI1 gene Proteins 0.000 description 1
- 101001048702 Homo sapiens RNA polymerase II elongation factor ELL2 Proteins 0.000 description 1
- 101000712571 Homo sapiens Ras-related protein Rab-8A Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101100152597 Homo sapiens TBX3 gene Proteins 0.000 description 1
- 101100207510 Homo sapiens TRIM32 gene Proteins 0.000 description 1
- 101000637031 Homo sapiens Trafficking protein particle complex subunit 9 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 101150030450 IRS1 gene Proteins 0.000 description 1
- JSZMKEYEVLDPDO-ACZMJKKPSA-N Ile-Cys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O JSZMKEYEVLDPDO-ACZMJKKPSA-N 0.000 description 1
- UCGDDTHMMVWVMV-FSPLSTOPSA-N Ile-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(O)=O UCGDDTHMMVWVMV-FSPLSTOPSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 101710151181 Inositol polyphosphate 5-phosphatase E Proteins 0.000 description 1
- 102100039349 Intraflagellar transport protein 25 homolog Human genes 0.000 description 1
- 102100030001 Intraflagellar transport protein 81 homolog Human genes 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 208000004252 Kleefstra syndrome Diseases 0.000 description 1
- 201000002772 Kwashiorkor Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000006302 Laron syndrome Diseases 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 208000000020 MEHMO syndrome Diseases 0.000 description 1
- 208000012708 MOMO syndrome Diseases 0.000 description 1
- 208000007715 MORM syndrome Diseases 0.000 description 1
- 101710195670 Meckelin Proteins 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100027383 Methyl-CpG-binding domain protein 1 Human genes 0.000 description 1
- 206010071706 Micropenis Diseases 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 101710095205 Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 1
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 1
- 101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101100013186 Mus musculus Fmr1 gene Proteins 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- CXISPYVYMQWFLE-UHFFFAOYSA-N N-D-alanyl-glycine Natural products CC(N)C(=O)NCC(O)=O CXISPYVYMQWFLE-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710151475 Neuroendocrine convertase 2 Proteins 0.000 description 1
- 102100034441 Neuroligin-4, X-linked Human genes 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 101100233339 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) irs-4 gene Proteins 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
- 101710184246 Nuclear receptor subfamily 0 group B member 2 Proteins 0.000 description 1
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101710199133 Nucleotide pyrophosphatase/phosphodiesterase Proteins 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 102000012547 Olfactory receptors Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 102100037757 Orexin Human genes 0.000 description 1
- 102000002131 PAS domains Human genes 0.000 description 1
- 108050009469 PAS domains Proteins 0.000 description 1
- 101150042788 PROK2 gene Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 102100028293 Period circadian protein homolog 1 Human genes 0.000 description 1
- KNPVDQMEHSCAGX-UWVGGRQHSA-N Phe-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UWVGGRQHSA-N 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 101710134447 Phosphatidylinositol polyphosphate 5-phosphatase type IV Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 101710100263 Plexin A3 Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000033873 Polysyndactyly Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710194543 Protein transport protein Sec16B Proteins 0.000 description 1
- 102100028964 Proteoglycan 3 Human genes 0.000 description 1
- 101710127914 Proteoglycan 3 Proteins 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102100023750 RNA polymerase II elongation factor ELL2 Human genes 0.000 description 1
- 208000037340 Rare genetic disease Diseases 0.000 description 1
- 102100033480 Ras-related protein Rab-8A Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 102000018673 SEC Translocation Channels Human genes 0.000 description 1
- 108010091732 SEC Translocation Channels Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 208000033712 Self injurious behaviour Diseases 0.000 description 1
- 102000015602 Septin Human genes 0.000 description 1
- 108050004875 Septin Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 101710173825 Short transient receptor potential channel 5 Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 102100035258 Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) Human genes 0.000 description 1
- 101710198702 Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- 241001284373 Spinus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 208000004265 Stomach Rupture Diseases 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042778 Syndactyly Diseases 0.000 description 1
- 102000027549 TRPC Human genes 0.000 description 1
- 108060008648 TRPC Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100031926 Trafficking protein particle complex subunit 9 Human genes 0.000 description 1
- 101710103131 Transmembrane protein 18 Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- SMDQRGAERNMJJF-JQWIXIFHSA-N Trp-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 SMDQRGAERNMJJF-JQWIXIFHSA-N 0.000 description 1
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 201000001875 X-linked intellectual disability-psychosis-macroorchidism syndrome Diseases 0.000 description 1
- 238000005162 X-ray Laue diffraction Methods 0.000 description 1
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000687 abdominal obesity-metabolic syndrome 3 Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Chemical group 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 101150050389 arl6 gene Proteins 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000007455 autophagic response Effects 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- QDHYJVJAGQLHBA-UHFFFAOYSA-N beta-Ala-Gly Chemical compound NCCC(=O)NCC(O)=O QDHYJVJAGQLHBA-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000000215 ciliated epithelial cell Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000018361 cognitive impairment - coarse facies - heart defects - obesity - pulmonary involvement - short stature - skeletal dysplasia syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 208000014765 congenital nongoitrous hypothyroidism 9 Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 208000022246 craniosynostosis-fibular aplasia syndrome Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- TUJWIYZCAPMHSA-UHFFFAOYSA-N dipentylphosphoryloxybenzene Chemical compound CCCCCP(=O)(CCCCC)OC1=CC=CC=C1 TUJWIYZCAPMHSA-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007008 genitalia development Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000031910 intraflagellar transport Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 108010021379 kendrin Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000002482 lateral meningocele syndrome Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000336 melanocortin receptor agonist Substances 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 201000000682 microcephalic osteodysplastic primordial dwarfism type II Diseases 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 102000004212 necdin Human genes 0.000 description 1
- 108090000771 necdin Proteins 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000029278 non-syndromic brachydactyly of fingers Diseases 0.000 description 1
- 208000029321 non-syndromic brachydactyly of toes Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 208000014258 obesity due to melanocortin 4 receptor deficiency Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000007138 otopalatodigital syndrome type 1 Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009892 regulation of energy homeostasis Effects 0.000 description 1
- 230000004314 regulation of intracellular transport Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 201000010622 retinitis pigmentosa 55 Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 208000019360 selective pituitary resistance to thyroid hormone Diseases 0.000 description 1
- 208000003126 selective pituitary thyroid hormone resistance Diseases 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000002957 synpolydactyly Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000007906 type 1 diabetes mellitus 2 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000006107 tyrosine sulfation Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 208000032620 x-linked multiple congenital anomalies-neurodevelopmental syndrome Diseases 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082867P | 2020-09-24 | 2020-09-24 | |
| US63/082,867 | 2020-09-24 | ||
| PCT/US2021/052032 WO2022067086A1 (en) | 2020-09-24 | 2021-09-24 | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116507353A true CN116507353A (zh) | 2023-07-28 |
Family
ID=80845850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180071771.8A Pending CN116507353A (zh) | 2020-09-24 | 2021-09-24 | 治疗黑皮质素-4受体通路相关病症的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240058414A1 (https=) |
| EP (1) | EP4216979A4 (https=) |
| JP (1) | JP2023542985A (https=) |
| KR (1) | KR20230095956A (https=) |
| CN (1) | CN116507353A (https=) |
| AR (1) | AR123603A1 (https=) |
| AU (1) | AU2021350017A1 (https=) |
| CA (1) | CA3192873A1 (https=) |
| CL (1) | CL2023000823A1 (https=) |
| CO (1) | CO2022009561A2 (https=) |
| MX (1) | MX2023003360A (https=) |
| TW (1) | TW202228760A (https=) |
| WO (1) | WO2022067086A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4554607A2 (en) * | 2022-07-12 | 2025-05-21 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
| WO2024108198A2 (en) * | 2022-11-18 | 2024-05-23 | Rhythm Pharmaceuticals, Inc. | Methods of treating obesity with an mc4r agonist |
| TW202535448A (zh) * | 2023-11-14 | 2025-09-16 | 美商律森製藥股份有限公司 | 鉀通道活化劑與mc4r促效劑之組合及相關使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565217A (en) * | 2005-07-08 | 2010-03-26 | Ipsen Pharma Sas | Melanocortin receptor ligands |
| EP2970388B1 (en) * | 2013-03-15 | 2018-07-25 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| PL3356386T3 (pl) * | 2015-09-30 | 2024-08-05 | Rhythm Pharmaceuticals, Inc. | Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4 |
-
2021
- 2021-09-24 AU AU2021350017A patent/AU2021350017A1/en active Pending
- 2021-09-24 US US18/028,117 patent/US20240058414A1/en active Pending
- 2021-09-24 MX MX2023003360A patent/MX2023003360A/es unknown
- 2021-09-24 KR KR1020237013822A patent/KR20230095956A/ko active Pending
- 2021-09-24 CA CA3192873A patent/CA3192873A1/en active Pending
- 2021-09-24 TW TW110135665A patent/TW202228760A/zh unknown
- 2021-09-24 CN CN202180071771.8A patent/CN116507353A/zh active Pending
- 2021-09-24 JP JP2023518779A patent/JP2023542985A/ja active Pending
- 2021-09-24 WO PCT/US2021/052032 patent/WO2022067086A1/en not_active Ceased
- 2021-09-24 AR ARP210102664A patent/AR123603A1/es unknown
- 2021-09-24 EP EP21873549.6A patent/EP4216979A4/en active Pending
-
2022
- 2022-07-07 CO CONC2022/0009561A patent/CO2022009561A2/es unknown
-
2023
- 2023-03-22 CL CL2023000823A patent/CL2023000823A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021350017A9 (en) | 2024-10-03 |
| TW202228760A (zh) | 2022-08-01 |
| KR20230095956A (ko) | 2023-06-29 |
| EP4216979A4 (en) | 2024-11-06 |
| AU2021350017A1 (en) | 2023-05-04 |
| CO2022009561A2 (es) | 2022-07-19 |
| US20240058414A1 (en) | 2024-02-22 |
| CA3192873A1 (en) | 2022-03-31 |
| EP4216979A1 (en) | 2023-08-02 |
| MX2023003360A (es) | 2023-06-23 |
| AR123603A1 (es) | 2022-12-21 |
| WO2022067086A1 (en) | 2022-03-31 |
| CL2023000823A1 (es) | 2023-09-15 |
| JP2023542985A (ja) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7752373B2 (ja) | メラノコルチン４受容体経路関連障害を治療する方法 | |
| CN116507353A (zh) | 治疗黑皮质素-4受体通路相关病症的方法 | |
| US20260001915A1 (en) | Methods for treating obesity with an mc4r agonist | |
| EP3539551B1 (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
| WO2026096815A1 (en) | Combinations of g-protein coupled hormone receptor modulators and melanocortin 4 receptor agonists and related methods of use | |
| RU2785889C1 (ru) | Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4 | |
| HK40110854A (en) | Method of treating melanocortin-4 receptor pathway-associated disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |